MX2020011401A - Tratamiento de combinacion para la fibrosis ocular y/o angiogenesis. - Google Patents

Tratamiento de combinacion para la fibrosis ocular y/o angiogenesis.

Info

Publication number
MX2020011401A
MX2020011401A MX2020011401A MX2020011401A MX2020011401A MX 2020011401 A MX2020011401 A MX 2020011401A MX 2020011401 A MX2020011401 A MX 2020011401A MX 2020011401 A MX2020011401 A MX 2020011401A MX 2020011401 A MX2020011401 A MX 2020011401A
Authority
MX
Mexico
Prior art keywords
angiogenesis
combination treatment
eye fibrosis
fibrosis
eye
Prior art date
Application number
MX2020011401A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2020011401A publication Critical patent/MX2020011401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen métodos para el diagnóstico, tratamiento y profilaxis de fibrosis y/o angiogénesis, en particular en el ojo. En modalidades particulares, los métodos emplean antagonismo de la señalización mediada por IL-11 y antagonismo de la angiogénesis. También se proporcionan combinaciones que comprenden un antagonista de la señalización mediada por IL-11 y un antagonista de un factor angiogénico.
MX2020011401A 2018-04-27 2019-04-26 Tratamiento de combinacion para la fibrosis ocular y/o angiogenesis. MX2020011401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1806918.7A GB201806918D0 (en) 2018-04-27 2018-04-27 Combination treatment for eye fibrosis
PCT/EP2019/060772 WO2019207122A1 (en) 2018-04-27 2019-04-26 Combination treatment for eye fibrosis and/or angiogenesis

Publications (1)

Publication Number Publication Date
MX2020011401A true MX2020011401A (es) 2021-01-08

Family

ID=62495028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011401A MX2020011401A (es) 2018-04-27 2019-04-26 Tratamiento de combinacion para la fibrosis ocular y/o angiogenesis.

Country Status (14)

Country Link
US (1) US20210238272A1 (es)
EP (1) EP3784282A1 (es)
JP (1) JP2021522272A (es)
KR (1) KR20210005125A (es)
CN (1) CN112399856A (es)
AU (1) AU2019258820A1 (es)
BR (1) BR112020021985A2 (es)
CA (1) CA3098340A1 (es)
CL (1) CL2020002774A1 (es)
EA (1) EA202092292A1 (es)
GB (1) GB201806918D0 (es)
MX (1) MX2020011401A (es)
PH (1) PH12020551786A1 (es)
WO (1) WO2019207122A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
TW202043276A (zh) 2019-01-21 2020-12-01 新加坡商新加坡保健服務私人有限公司 肝毒性之治療
GB201902419D0 (en) * 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
TW202108606A (zh) 2019-05-03 2021-03-01 新加坡商新加坡保健服務私人有限公司 代謝性疾病之治療及預防
GB202009292D0 (en) * 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
US20230257458A1 (en) * 2020-08-13 2023-08-17 Sunshine Lake Pharma Co., Ltd. Antibody of il-11 and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
AU2013362909A1 (en) * 2012-12-18 2015-05-21 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017141032A1 (en) * 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders

Also Published As

Publication number Publication date
US20210238272A1 (en) 2021-08-05
KR20210005125A (ko) 2021-01-13
EP3784282A1 (en) 2021-03-03
CL2020002774A1 (es) 2021-02-05
CA3098340A1 (en) 2019-10-31
CN112399856A (zh) 2021-02-23
PH12020551786A1 (en) 2021-05-10
GB201806918D0 (en) 2018-06-13
AU2019258820A1 (en) 2020-12-17
BR112020021985A2 (pt) 2021-01-26
WO2019207122A1 (en) 2019-10-31
JP2021522272A (ja) 2021-08-30
EA202092292A1 (ru) 2021-04-06

Similar Documents

Publication Publication Date Title
PH12020551786A1 (en) Combination treatment for eye fibrosis and/or angiogenesis
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
TN2017000483A1 (en) Triazole agonists of the apj receptor.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MY186271A (en) Ophthalmic compositions and methods of use therefor
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
GB201815025D0 (en) Insect-pathogenic fungus, spores, composition and use of same
PH12020550255A1 (en) Treatment of smc mediated disease
MX2019015150A (es) Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión.
IL280191A (en) Dissolved dosages, methods and use
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
PH12020550185A1 (en) Semaglutide in medical therapy
GB2543723A (en) Polyphenol compositions
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
MX2017013879A (es) Composiciones que comprenden anakinra.
EP3758688C0 (en) NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF EYE PAIN